Effect Of GM1 On PD-MCI And Plasma Phospholipid Level In PD-MCI Patients

Objective: Study of Parkinson's disease with mild cognitive impairment(PD-MCI)changes of plasma phospholipid levels in patients,and to further explore the monosialo four hexose Ganglioside(GM1)on Parkinson's disease and mild cognitive impairment(PD-MCI)effect and influence on the plasma PD-MCI level in patients with phospholipid.Information and methods: From October 2015 to June 2017,186 cases of Parkinson's disease were collected in the hospital,all patients were treated with UPDRS-III and MoCA assessment,found 56 cases of patients with mild cognitive impairment,according to the results using a random number table method were randomly divided into treatment group 28(A group)and control group(B group)28,and randomly selected 28 cases of PD patients without PD-MCI symptoms as the control group(C group)and three groups(A,B,C group)in healthy population of patients with general information similar to the28 people as healthy control group(D group),before treatment all subjects underwent plasma phospholipid content was measured and compared the results of statistical analysis,the total plasma phospholipid content was measured in the study.In the next 6weeks,B group and C group received routine drug therapy for Parkinson's disease.A group was treated with single sialic acid four hexose Ganglioside(GM1)on the basis of routine drug treatment,and GM1 100 mg QD was used for intravenous drip.After 6 weeks of treatment,the subjects in group A and group B received the determination of plasma phospholipid level and the evaluation of UPDRS-III and MoCA.Use Excel to collect all the data and use SPSS 17 software for statistical analysis.Results: Before treatment,the plasma phospholipid levels in group A,B and C were significantly higher than those in group D,and the difference was statistically significant(P value < 0.05).There was no significant difference in plasma phospholipid level between group A and group B,but it was higher than that in group C and group A(P value < 0.05).Plasma phospholipid levels in group A were significantly lower than those in group B after 6 weeks of treatment(P value < 0.05).The MoCA score of group A was higher than that of group B and the UPDRS-III score of group A was lower than that of group B(P value < 0.05).The differences were statistically significant.Conclusion:1.The plasma phospholipid level in PD patients was higher than that in normal controls,and the increase of plasma phospholipid level was correlated with the occurrence of PD-MCI.The plasma phospholipid level might be used as a potential biochemical marker for the early diagnosis of PD-MCI.2.Tetrahexose monosialoganglioside(GM1)can reduce plasma phospholipid level in patients with PD-MCI,promote the synthesis and reuse of phospholipid,reduce the damage of the pathological factors on the cell membrane,stabilize the damaged nerve cell membrane,have certain neuroprotective effect,and have a certain decline in the cognitive function of PD-MCI patients.The retarding effect may even improve the exercise symptoms,and it also improves the motor symptoms of PD patients.